Simcere Pharmaceutical Group Limited (FRA:S2P)

Market Cap	3.46B
Revenue (ttm)	878.05M
Net Income (ttm)	97.02M
Shares Out	n/a
EPS (ttm)	0.04
PE Ratio	35.62
Forward PE	24.93
Dividend	0.02 (1.72%)
Ex-Dividend Date	Jun 18, 2024

Volume	n/a
Average Volume	56
Open	1.220
Previous Close	1.220
Day's Range	1.220 - 1.220
52-Week Range	0.585 - 1.220
Beta	n/a
RSI	70.59
Earnings Date	Aug 21, 2025

About FRA:S2P

Simcere Pharmaceutical Group Limited engages in the research, development, manufacture, and sale of pharmaceutical products to distributors, pharmacy chains, and other pharmaceutical manufacturers in China. The company focuses on various therapeutic areas, including oncology, central nervous system, autoimmune, anti-infection, cardiovascular, and others. Its principal products include Sanbexin, an edaravone and dexborneol concentrated solution for injection; Endostar, a recombinant human endostatin injection; ENWEIDA, an envafolimab injection; ...

• Industry: Pharmaceutical Preparations
• Founded: 1995
• Employees: 6,584
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: S2P

Financial Performance

In 2024, FRA:S2P's revenue was 6.64 billion, an increase of 0.41% compared to the previous year's 6.61 billion. Earnings were 733.17 million, an increase of 2.57%.

Financial numbers in CNY